The management of diabetes mellitus by mangiferin: advances and prospects

Nanoscale. 2022 Feb 10;14(6):2119-2135. doi: 10.1039/d1nr06690k.

Abstract

Diabetes mellitus has become one of the most challenging public health problems today. There are still various deficiencies that remain in existing therapeutic drugs. With increasing prevalence and mortality rates, more effective therapeutic agents are required for treatment clinically. As a kind of polyphenol and as a natural product, mangiferin has numerous pharmacological and excellent effects. In this review, the underlying mechanisms of mangiferin on diabetes mellitus and complications will be summarized. Moreover, mangiferin belongs to the BSC IV class and the clinical application and development of mangiferin are limited due to its poor aqueous solubility and fat solubility as well as low bioavailability. Our review also elaborated on improving the solubility of mangiferin by changing the dosage form and introduced the existing results, which hope to provide useful reference for mangiferin for further treating diabetes. In conclusion, mangiferin might be a potential adjuvant therapy for the treatment of diabetes mellitus and complications in the future.

Publication types

  • Review

MeSH terms

  • Biological Availability
  • Diabetes Mellitus* / drug therapy
  • Humans
  • Solubility
  • Xanthones* / therapeutic use

Substances

  • Xanthones
  • mangiferin